Catalyst

Slingshot members are tracking this event:

FDA approves Tesaro's (TSRO) ZEJULA (niraparib), a PARP inhibitor that treats adults with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
TSRO Community voting in process
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 27, 2017
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Zejula, Niraparib, Parp Inhibitor, Peritoneal, Fallopian Tube, Epithelial Ovarian, Cancer Treatment